Citations

Showing 10 of 108081 citations.

Impact of Smoke Evacuation on Patient Experience During Mohs Surgery
Yonan, Yousif , Ochoa, Shari A.

Mayo Clinic

Dermatologic Surgery | May 27, 2017 | Volume: 43 | Issue: 11 | Pages: 1363-1366

10.1097/dss.0000000000001195 | PMID 28562439 Get It

BACKGROUND There have been several investigations into possible health risks of surgical smoke exposure, and it has previously been associated with harboring pathogens and carcinogens. Patients in the authors' practice have expressed that the odor from the smoke created by electrosurgical equipment is unpleasant. OBJECTIVE The authors sought to determine if smoke evacuation decreases patient perception of smoke created by electrosurgery during Mohs surgery and if it subsequently improves patient satisfaction with their surgical experience by minimizing the associated odor. MATERIALS AND METHODS Thirty patients were enrolled in this comparative trial. Smoke evacuation was used during closure but not during Mohs stages. Patients were queried regarding their experience and preferences during and at the end of the procedure. RESULTS 100% of patients reported the perception of a burning odor during removal of Mohs stages, compared with 40% reporting the perception of a burning odor during closure. During the Mohs stages, 66.6% of patients reported the odor as unpleasant compared with 16.6% of patients during closure. There were no statistically significant differences in patient perceptions when stratified by age, sex, or surgical site. CONCLUSION The authors believe that using a wall suction smoke evacuation system is simple and can result in a more pleasant experience for patients undergoing Mohs surgery.
Accuracy of Capillary and Arterial Whole Blood Glucose Measurements Using a Glucose Meter in Patients under General Anesthesia in the Operating Room
Karon, Brad S. , Larsen, Chelsie M., Siebenaler, Lindsay K., Wells, Amy E., Wood‐Wentz, Christina M. , Shirk-Marienau, Mary E., Curry, Timothy B. , Donato, Leslie J.

Mayo Clinic

Anesthesiology | May 27, 2017 | Volume: 127 | Issue: 3 | Pages: 466-474

10.1097/aln.0000000000001708 | PMID 28557817 Get It

Abstract Background The aim of this study was to evaluate the use of a glucose meter with surgical patients under general anesthesia in the operating room. Methods Glucose measurements were performed intraoperatively on 368 paired capillary and arterial whole blood samples using a Nova StatStrip (Nova Biomedical, USA) glucose meter and compared with 368 reference arterial whole blood glucose measurements by blood gas analyzer in 196 patients. Primary outcomes were median bias (meter minus reference), percentage of glucose meter samples meeting accuracy criteria for subcutaneous insulin dosing as defined by Parkes error grid analysis for type 1 diabetes mellitus, and accuracy criteria for intravenous insulin infusion as defined by Clinical and Laboratory Standards Institute guidelines. Time under anesthesia, patient position, diabetes status, and other variables were studied to determine whether any affected glucose meter bias. Results Median bias (interquartile range) was −4 mg/dl (−9 to 0 mg/dl), which did not differ from median arterial meter bias of −5 mg/dl (−9 to −1 mg/dl; P = 0.32). All of the capillary and arterial glucose meter values met acceptability criteria for subcutaneous insulin dosing, whereas only 89% (327 of 368) of capillary and 93% (344 of 368) arterial glucose meter values met accuracy criteria for intravenous insulin infusion. Time, patient position, and diabetes status were not associated with meter bias. Conclusions Capillary and arterial blood glucose measured using the glucose meter are acceptable for intraoperative subcutaneous insulin dosing. Whole blood glucose on the meter did not meet accuracy guidelines established specifically for more intensive ( e.g. , intravenous insulin) glycemic control in the acute care environment.
Beta-2 Adrenergic Receptor Genotype Influences Power Output in Healthy Subjects
Kelley, Eli F. , Johnson, Bruce D., Snyder, Eric M.

Mayo Clinic

Journal of Strength and Conditioning Research | May 27, 2017 | Volume: 31 | Issue: 8 | Pages: 2053-2059

10.1519/jsc.0000000000001978 | PMID 28557859 Get It

Abstract Kelley, EF, Johnson, BD, and Snyder, EM. Beta-2 adrenergic receptor genotype influences power output in healthy subjects. J Strength Cond Res 31(8): 2053–2059, 2017—The purpose of this study was to determine the effects of ADRB2 genotypes on muscle function (absolute power and relative power) in healthy subjects. We performed genotyping of the ADRB2 (amino acid 16) and high-intensity, steady-state exercise on 77 healthy subjects (AA = 18, AG = 25, GG = 34). There were no differences between genotype groups in age, height, weight, or body mass index (BMI) (age = 28.9 ± 5.7 years, 27.9 ± 5.7 years, 29.2 ± 5.9 years, height = 170.7 ± 8.6 cm, 174.9 ± 8.7 cm, 173.4 ± 9.6 cm, weight = 68.5 ± 13.0 kg, 75.0 ± 12.9 kg, 74.4 ± 12.9 kg, and BMI = 23.4 ± 3.9, 24.4 ± 2.9, 24.7 ± 3.4, for AA, AG, and GG, respectively). The genotype groups differed significantly in watts, and watts/V̇ o 2 with heavy exercise (watts = 186.3 ± 54.6, 237.8 ± 54.4, 219.4 ± 79.5, watts/V̇ o 2 = 0.08 ± 0.006, 0.09 ± 0.005, 0.08 ± 0.006). There was a trend toward significance ( p = 0.058) for W·kg −1 (2.7 ± 0.4, 3.2 ± 0.5, 2.9 ± 0.8, for AA, AG, and GG, respectively). These data suggest that genetic variation of the ADRB2 may influence relative strength in healthy subjects and may become an important genetic determinant of muscular strength and functional capacity in patients with diseases that result in a loss of muscle strength.
The Influence of Word Frequency on Word Retrieval: Measuring Covert Behaviors
Chih, Yu-Chun, Stierwalt, Julie A. G., LaPointe, Leonard L., Chih, Yu-Pin, Chih, Yu-Pin, Chih, Yu‐Chun , Chih, Yu-Pin, Chih, Yu-Pin

Mayo Clinic

Communication Disorders Quarterly | May 27, 2017 | Volume: 39 | Issue: 1 | Pages: 288-292

10.1177/1525740116686311 Get It

Physiological activities (heart rate and respiratory rate) during a word retrieval task were measured in normal participants. Word frequency demonstrated a significant effect on naming accuracy and latencies but not on physiological activities. These data will serve as a basis for comparison for individuals with a compromised language system.
BCL6 represses antiviral resistance in follicular T helper cells
Amet, Tohti, Son, Young Min , Jiang, Li , Cheon, In Su , Huang, Su, Gupta, Samir K. , Montaner, Luis J. , Yu, Qigui , Dent, Alexander L. , Sun, Jie

Mayo Clinic

Journal of Leukocyte Biology | May 27, 2017 | Volume: 102 | Issue: 2 | Pages: 527-536

10.1189/jlb.4a1216-513rr | PMID 28550121 Get It

Abstract Follicular Th (Tfh) cells are a distinct subset of Th cells that help B cells produce class-switched antibodies. Studies have demonstrated that Tfh cells are highly prone to HIV infection and replication. However, the molecular mechanisms underlying this phenomenon are largely unclear. Here, we show that murine and human Tfh cells have diminished constitutive expression of IFN-stimulated genes (ISGs) inclusive of antiviral resistance factor MX dynamin-like GTPase 2 (MX2) and IFN-induced transmembrane 3 (IFITM3) compared with non-Tfh cells. A lower antiviral resistance in Tfh was consistent with a higher susceptibility to retroviral infections. Mechanistically, we found that BCL6, a master regulator of Tfh cell development, binds to ISG loci and inhibits the expression of MX2 and IFITM3 in Tfh cells. We demonstrate further that inhibition of the BCL6 BR-C, ttk, and bab (BTB) domain function increases the expression of ISGs and suppresses HIV infection and replication in Tfh cells. Our data reveal a regulatory role of BCL6 in inhibiting antiviral resistance factors in Tfh cells, thereby promoting the susceptibility Tfh cells to viral infections. Our results indicate that the modulation of BCL6 function in Tfh cells could be a potential strategy to enhance Tfh cell resistance to retroviral infections and potentially decrease cellular reservoirs of HIV infection.
Risk of Severe Hypoglycemia in Type 1 Diabetes Over 30 Years of Follow-up in the DCCT/EDIC Study
Gubitosi‐Klug, Rose , Braffett, Barbara H. , White, Neil H. , Sherwin, Robert S., Service, F. John, Lachin, John M. , Tamborlane, William V. , Gubitosi-Klug, Rose A

Mayo Clinic

Diabetes Care | May 27, 2017 | Volume: 40 | Issue: 8 | Pages: 1010-1016

10.2337/dc16-2723 | PMID 28550194 Get It

OBJECTIVE During the Diabetes Control and Complications Trial (DCCT), intensive diabetes therapy achieving a mean HbA1c of ∼7% was associated with a threefold increase in the rate of severe hypoglycemia (defined as requiring assistance) compared with conventional diabetes therapy with a mean HbA1c of 9% (61.2 vs. 18.7 per 100 patient-years). After ∼30 years of follow-up, we investigated the rates of severe hypoglycemia in the DCCT/Epidemiology of Diabetes Inverventions and Complications (EDIC) cohort. RESEARCH DESIGN AND METHODS Rates of severe hypoglycemia were reported quarterly during DCCT and annually during EDIC (i.e., patient recall of episodes in the preceding 3 months). Risk factors influencing the rate of severe hypoglycemia over time were investigated. RESULTS One-half of the DCCT/EDIC cohort reported episodes of severe hypoglycemia. During EDIC, rates of severe hypoglycemia fell in the former DCCT intensive treatment group but rose in the former conventional treatment group, resulting in similar rates (40.8 vs. 36.6 episodes per 100 patient-years, respectively) with a relative risk of 1.12 (95% CI 0.91–1.37). A preceding episode of severe hypoglycemia was the most powerful predictor of subsequent episodes. Entry into the DCCT study as an adolescent was associated with an increased risk of severe hypoglycemia, whereas insulin pump use was associated with a lower risk. Severe hypoglycemia rates increased with lower HbA1c similarly among participants in both treatment groups. CONCLUSIONS Rates of severe hypoglycemia have equilibrated over time between the two DCCT/EDIC treatment groups in association with advancing duration of diabetes and similar HbA1c levels. Severe hypoglycemia persists and remains a challenge for patients with type 1 diabetes across their life span.
Atrial Natriuretic Peptide ― Old But New Therapeutic in Cardiovascular Diseases ―
Ichiki, Tomoko , Burnett, John C.

Mayo Clinic

Circulation Journal | May 26, 2017 | Volume: 81 | Issue: 7 | Pages: 913-919

10.1253/circj.cj-17-0499 | PMID 28552863 Get It

Recommendations on the use of magnetic resonance imaging in PSC‐A position statement from the International PSC Study Group
Eaton, John E. , Ringe, Kristina I. , Venkatesh, Sudhakar K. , Yamamura, Jin , IPSCSG, for the MRI working group of the, Eaton, John, Venkatesh, Sudhakar, Schramm, Christoph , IPSCSG, for the MRI working group of the, Venkatesh, Sudhakar K

Mayo Clinic

Hepatology | May 26, 2017 | Volume: 66 | Issue: 5 | Pages: 1675-1688

10.1002/hep.29293 | PMID 28555945 Get It

Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disorder characterized by inflammation and fibrosis of the intra‐ and/or extrahepatic bile ducts. Magnetic resonance imaging (MRI) is a noninvasive imaging modality that can be used to diagnose PSC and detect disease related complications. Quantitative MRI technologies also have the potential to provide valuable prognostic information. Despite the potential of this imaging technology, the clinical application of MRI in the care of PSC patients and imaging standards vary across institutions. Moreover, a unified position statement about the role of MRI in the care of PSC patients, quality imaging standards, and its potential as a research tool is lacking. Conclusion : Members of the International PSC Study Group and radiologists from North America and Europe have compiled the following position statement to provide guidance regarding the application of MRI in the care of PSC patients, minimum imaging standards, and future areas of research. (H epatology 2017;66:1675–1688).
Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma
Arbelaiz, Ander, Azkargorta, Mikel , Krawczyk, Marcin , Santos‐Laso, Álvaro , Lapitz, Ainhoa , Perugorria, María J. , González, Esperanza , Jiménez-Agüero, Raúl , Casta, Adelaida La , Ibarra, Cesar , Sanchez‐Campos, Alberto, Jimeno, J.P., Lammert, Frank , Milkiewicz, Piotr , Marzioni, Marco , Marı́n, José J.G. , Martínez, I. Mascarell, Elortza, Félix , Falcón‐Pérez, Juan Manuel , Bujanda, Luís , Bañales, Jesús M. , Erice, Oihane , Macı́as, Rocı́o I.R. , Patel, Tushar , Gores, Gregory J. , Marzioni, Marco , Banales, Jesus M , Falcón-Perez, Juan Manual , Milkiewicz, Piotr , Bujanda, L.

Mayo Clinic

Hepatology | May 26, 2017 | Volume: 66 | Issue: 4 | Pages: 1125-1143

10.1002/hep.29291 | PMID 28555885 Get It

Cholangiocarcinoma (CCA) includes a heterogeneous group of biliary cancers with poor prognosis. Several conditions, such as primary sclerosing cholangitis (PSC), are risk factors. Noninvasive differential diagnosis between intrahepatic CCA and hepatocellular carcinoma (HCC) is sometimes difficult. Accurate noninvasive biomarkers for PSC, CCA, and HCC are not available. In the search for novel biomarkers, serum extracellular vesicles (EV) were isolated from CCA (n = 43), PSC (n = 30), or HCC (n = 29) patients and healthy individuals (control, n = 32); and their protein content was characterized. By using nanoparticle tracking analysis, serum EV concentration was found to be higher in HCC than in all the other groups. Round morphology (by transmission electron microscopy), size (∼180 nm diameter by nanoparticle tracking analysis), and markers (clusters of differentiation 9, 63, and 81 by immunoblot) indicated that most serum EV were exosomes. Proteome profiles (by mass spectrometry) revealed multiple differentially expressed proteins among groups. Several of these proteins showed high diagnostic values with maximum area under the receiver operating characteristic curve of 0.878 for CCA versus control, 0.905 for CCA stage I‐II versus control, 0.789 for PSC versus control, 0.806 for noncirhottic PSC versus control, 0.796 for CCA versus PSC, 0.956 for CCA stage I‐II versus PSC, 0.904 for HCC versus control, and 0.894 for intrahepatic CCA versus HCC. Proteomic analysis of EV derived from CCA human cells in vitro revealed higher abundance of oncogenic proteins compared to EV released by normal human cholangiocytes. Orthotopic implant of CCA human cells in the liver of immunodeficient mice resulted in the release to serum of EV containing some similar human oncogenic proteins. Conclusion : Proteomic signatures found in serum EV of CCA, PSC, and HCC patients show potential usefulness as diagnostic tools. (H epatology 2017;66:1125‐1143).
A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis
Palladini, Giovanni , Kukreti, Vishal , Zonder, Jeffrey A. , Cohen, Adam D. , Seldin, David C. , Schönland, Stefan , Berg, Deborah, Yang, Huyuan, Gupta, Neeraj , Hui, Ai-Min, Comenzo, Raymond L. , Merlini, Giampaolo , Sanchorawala, Vaishali , Dispenzieri, Angela , Jaccard, Arnaud , Gupta, Neeraj , Merlini, Giampaolo , Cohen, Adam D , Schönland, Stefan , Palladini, Giovanni

Mayo Clinic

Blood | May 26, 2017 | Volume: 130 | Issue: 5 | Pages: 597-605

10.1182/blood-2017-03-771220 | PMID 28550039 Get It

Abstract This phase 1/2 study assessed the safety, tolerability, and preliminary efficacy of the oral proteasome inhibitor (PI) ixazomib in patients with relapsed/refractory immunoglobulin light chain (AL) amyloidosis. Ixazomib was administered to adult patients with relapsed/refractory AL amyloidosis after 1 or more prior lines of therapy (including bortezomib) on days 1, 8, and 15 of 28-day cycles, for up to 12 cycles. Patients with less than partial response after 3 cycles received oral dexamethasone (40 mg, days 1-4) from cycle 4. A 3+3 dose-escalation phase was followed by 2 expansion cohorts (PI-naive and PI-exposed patients) at the maximum tolerated dose (MTD). Twenty-seven patients were enrolled: 11 during dose escalation (6 at 4.0 mg and 5 at 5.5 mg) and 16 during dose expansion (4.0 mg). Three patients experienced dose-limiting toxicities: 1 at 4.0 mg and 2 at 5.5 mg; the MTD was determined as 4.0 mg. Most common adverse events (AEs) included nausea, skin and subcutaneous tissue disorders (SSTD), diarrhea, and fatigue; grade 3 or higher AEs included dyspnea, fatigue, and SSTD. Overall, the hematologic response rate was 52% in patients treated at the MTD (n = 21). Organ responses were seen in 56% of patients (5 cardiac, 5 renal). Median hematologic progression-free survival was 14.8 months; 1-year progression-free and overall survival rates were 60% and 85%, respectively (median follow-up, 16.9 months). Weekly oral ixazomib appears to be active in patients with relapsed/refractory AL amyloidosis, with a generally manageable safety profile. The study was registered at clinicaltrials.gov as #NCT01318902. A phase 3 study is ongoing (#NCT01659658).